Phenolphthaleinphosphat

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: Phenolphthaleinphosphat
• 英文别名: [4-[1-(4-hydroxyphenyl)-3-oxo-2-benzofuran-1-yl]phenyl] dihydrogen phosphate
• 化学式: C₂₀H₁₅O₇P
• 分子量: 398.3
• InChiKey: NEMOXUWHWHQWJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS<br/>[FR] COMPOSÉS SULFONAMIDES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TNAP
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2013126608A1

  公开（公告）日：2013-08-29

  Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper- mineralization.

  本发明描述了调节TNAP活性的化合物。在某些实施例中，本发明描述的化合物抑制TNAP。在某些实施例中，本发明描述的化合物可用于治疗与过度矿化相关的病症。
• METHOD FOR THE VACCINATION AGAINST HIV
  申请人：BIONOR IMMUNO AS

  公开号：US20170000876A1

  公开（公告）日：2017-01-05

  The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel methods to select HIV infected patients with improved responses to HIV-specific vaccine peptides.

  本发明涉及新型活性剂组合物和治疗HIV感染和艾滋病的方法。具体而言，本发明涉及用于选择对HIV特异性疫苗肽具有改善反应的HIV感染患者的新方法。
• Methods and formulations for reducing circulating antibodies
  申请人：——

  公开号：US20010010818A1

  公开（公告）日：2001-08-02

  The invention provides methods for reducing circulating levels of antibodies, particularly disease-associated antibodies. The methods entail administering effective amounts of epitope-presenting carriers to an individual. In other embodiments, ex vivo methods for reducing circulating levels of antibodies are provided which employ epitope-presenting carriers.

  本发明提供了降低循环抗体水平的方法，特别是疾病相关抗体。该方法包括向个体施用有效剂量的表位呈现载体。在其他实施例中，本发明提供了利用表位呈现载体的体外降低循环抗体水平的方法。
• Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same
  申请人：Marquis M. David

  公开号：US20050004351A1

  公开（公告）日：2005-01-06

  The present invention provides domain 1 β 2 GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 β 2 GPI polypeptides and mimetics. Domain 1 of β 2 GPI has been shown to bind to anti-cardiolipin (β 2 GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 β 2 GPI polypeptides may be used to detect β 2 GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 β 2 GPI polypeptides.

  本发明提供了1区β2GPI多肽、编码这些多肽的多核苷酸、这些多肽的类似物以及使用1区β2GPI多肽和类似物的方法。已经证明β2GPI的1区能够结合抗心磷脂（β2GPI依赖性抗磷脂抗体），这些抗体与多种病理学如血栓形成和胎儿流产有关。1区β2GPI多肽可用于检测样品中的β2GPI依赖性抗磷脂抗体。本发明还提供了使用这些1区β2GPI多肽诱导耐受的方法。
• APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
  申请人：——

  公开号：US20040009904A1

  公开（公告）日：2004-01-15

  aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provides as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

  本文公开了一种能够与aPL表位结合的B细胞特异性结合的aPL类似物。优化的类似物缺乏T细胞表位，可用作治疗aPL抗体介导疾病的结合物。提供了包括aPL类似物和非免疫原价位平台分子的结合物，以及新型的非免疫原价位平台分子和连接剂。公开了制备和鉴定该类似物的方法，使用该类似物进行治疗的方法和组合物，以及用于aPL抗体的诊断免疫分析的方法和组合物。